Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice

Up to two-thirds of patients affected by spinal cord injury (SCI) develop central neuropathic pain (CNP), which has a high impact on their quality of life. Most of the patients are largely refractory to current treatments, and new pharmacological strategies are needed. Recently, it has been shown th...

Descripción completa

Detalles Bibliográficos
Autores principales: Castany, Sílvia, Codony, Xavier, Zamanillo, Daniel, Merlos, Manuel, Verdú, Enrique, Boadas-Vaello, Pere
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439356/
https://www.ncbi.nlm.nih.gov/pubmed/30967775
http://dx.doi.org/10.3389/fphar.2019.00222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439356/
https://www.ncbi.nlm.nih.gov/pubmed/30967775
http://dx.doi.org/10.3389/fphar.2019.00222

Ejemplares similares